GeneBioTech Co. Ltd
Genebiotech Co., Ltd., a specialized fermentation company, researches, develops, produces, and sells biological resources for use in animal resources, agriculture, food, medicine, etc. It offers functional feed ingredients and additives, as well as veterinary medicines. The company was founded in 1984 and is headquartered in Gongju, South Korea.
GeneBioTech Co. Ltd (086060) - Total Liabilities
Latest total liabilities as of September 2025: ₩21.41 Billion KRW
Based on the latest financial reports, GeneBioTech Co. Ltd (086060) has total liabilities worth ₩21.41 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
GeneBioTech Co. Ltd - Total Liabilities Trend (2009–2024)
This chart illustrates how GeneBioTech Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
GeneBioTech Co. Ltd Competitors by Total Liabilities
The table below lists competitors of GeneBioTech Co. Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
China HK Power Smart Energy Group Limited
OTCGREY:CHNTF
|
USA | $1.45 Billion |
|
Voltaic Minerals Corp
V:VLT
|
Canada | CA$3.21 Million |
|
Pioneer Bankshares Inc
PINK:PNBI
|
USA | $304.96 Million |
|
BBIA Co., Ltd.
KQ:451250
|
Korea | ₩11.22 Billion |
|
Anli International Co Ltd
TWO:5223
|
Taiwan | NT$1.45 Billion |
|
Wotso
AU:WOT
|
Australia | AU$169.34 Million |
|
Habco Trans Maritima
JK:HATM
|
Indonesia | Rp272.19 Billion |
|
Earlyworks Co., Ltd. American Depositary Shares
NASDAQ:ELWS
|
USA | $116.47 Million |
Liability Composition Analysis (2009–2024)
This chart breaks down GeneBioTech Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.53 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.40 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.28 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how GeneBioTech Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for GeneBioTech Co. Ltd (2009–2024)
The table below shows the annual total liabilities of GeneBioTech Co. Ltd from 2009 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩21.02 Billion | +18.65% |
| 2023-12-31 | ₩17.71 Billion | -3.29% |
| 2022-12-31 | ₩18.31 Billion | +11.52% |
| 2021-12-31 | ₩16.42 Billion | -3.64% |
| 2020-12-31 | ₩17.04 Billion | -18.86% |
| 2019-12-31 | ₩21.00 Billion | -14.84% |
| 2018-12-31 | ₩24.66 Billion | +29.44% |
| 2017-12-31 | ₩19.05 Billion | -5.37% |
| 2016-12-31 | ₩20.14 Billion | -1.17% |
| 2015-12-31 | ₩20.37 Billion | -14.83% |
| 2014-12-31 | ₩23.92 Billion | -5.26% |
| 2013-12-31 | ₩25.25 Billion | +3.06% |
| 2012-12-31 | ₩24.50 Billion | -8.54% |
| 2011-12-31 | ₩26.79 Billion | +139.51% |
| 2010-12-31 | ₩11.18 Billion | -0.83% |
| 2009-12-31 | ₩11.28 Billion | -- |